Lutsiak et al., 2005; Ghiringhelli et al., 2007), by triggering the maturation of tumor-infiltrating dendritic cells (Tanaka et al., 2009), or by disrupting cancer stem cell–promoting vascular niches nHighlight:LDM therapy yielded an average response rate of 39% and an average overall clinical benefit of 57%nHighlight:LDM therapy in CAF-abundant, desmoplastic cancers, which is mediated through an attenuated STAT-1 and NF-κB activation in CAFs leading to a substantially reduced ELR+ chemokine production, thereby significantly tempering the therapy-triggered stromal pro-oncogenic activitnHighlight:chemotherapy led to the enrichment of IL-17A–producing CAFs within the tumor stroma, which in turn promoted the self-renewal of TICs and tumor growthnHighlight:MTD chemotherapy used to treat human cancers can exert sustained effects on the tumor stroma that include the induction of an ELR+ chemokine–producing phenotype in CAFs, whereby they can subsequently promote tumor aggressionnHighlight:LDM chemotherapy may provide a new avenue for preventing stromal activationnHighlight:crucial contribution of the tissue stroma in cancer treatmentn]]>

About Dr. Nathan Goodyear
About Dr. Nathan Goodyear

Dr. Nathan Goodyear, a medical doctor with years of experience in the field of integrative cancer care, has announced the launch of an online training program. This program, available on his new website, will provide individuals with access to video trainings led by Dr. Goodyear himself, covering a range of topics related to integrative cancer care. These trainings will include information on the latest research and techniques in the field, as well as guidance on how to incorporate these approaches into a patient’s overall cancer treatment plan. With this online program, Dr. Goodyear hopes to make his expertise and knowledge more widely accessible, and help more people understand the benefits of integrative cancer care.


Leave a Comment

Your email address will not be published. Required fields are marked *

Skip to content